2026 Q2 - tulosraportti
19 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 472 | - | - | ||
| 1 528 | - | - | ||
| 2 500 | - | - | ||
| 3 385 | - | - | ||
| 3 778 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenThought I'd share some thoughts on Circio's strategy going forward, especially the delivery side and how the capital from the latest round – and a potential repair issue – can be used. Circio owns the expression engine (circVec), but delivery still needs to be solved. Therefore, they are testing several things in parallel. Named collaborations on the delivery/vector side: • Acuitas – T-cell-tropic LNP (reported long-lasting expression) • Full Circles – C4DNA (minicircular format, potential for lower immune activation and re-dosing) • Tcelltech – nanoSMAR (large payload, non-integrating DNA vector) • United Immunity – CAR-M / myeloid-directed • TraffikGene – peptide-based non-viral delivery In addition, the company has several unnamed tracks. According to H1/webcast, there are about 11 active collaborations within in vivo cell therapy (divided into T-cell delivery, DNA vector formats, and other applications), plus a number of gene therapy collaborations (incl. top-5 pharma). The goal is to find the combination of circVec + delivery that provides the best expression and function before talking about clinic. What the first ~200 MNOK can be used for: • Intensive screening of LNPs and DNA vectors • Secure access to the most promising delivery technology – primarily via license / option – possibly smaller technology acquisitions (IP/asset), not full acquisition • Finance functional PoC studies (CAR expression + actual activity against target cells) • Advance preclinical development, primate validation and prepare CMC/IND A potential repair issue is not set in stone. It can be canceled if the share trades below the subscription price over time. If it is carried out, it provides: • Stronger negotiating position in licensing • Greater room for maneuver for smaller strategic acquisitions / technology acquisitions • More extensive preclinical programs and deeper primate validation • Better funded CMC and IND preparations • A buffer to build upon the technology that actually works best Large, established delivery companies are out of reach anyway. The realistic options are licenses with options, smaller asset acquisitions, or – with extra capital – a small early-stage acquisition. The order seems logical: 1. Screening 2. Find the right delivery 3. Connect it with circVec 4. Functional in vivo CAR-T PoC 5. Primate validation 6. CMC / preclinical development 7. Clinic If they manage to make this chain connect, they will have elevated the company from an expression technology to a more complete in vivo CAR-T platform. There is still much that needs to be proven – especially that the signal actually comes from the T-cells and that it functions functionally. But with the capital in place, they at least have the opportunity to test it properly. Anyone else have thoughts on this?
·1 t sittenBeyond the residents of the echo chamber's daily analyses of today's closing price, recommendations to hold or buy more on every dip, they also operate morally on a higher level. Losses don't matter either because one is, after all, supporting important medical research. The moral indignation is clearly expressed towards the traders. Long ago given the label "øretrillere". While FOMO is cultivated daily with stories about the train -the one train- that is about to leave the platform, the traders ensure liquidity in the stock. We have all been stuck in stocks without turnover. Time and again Circio goes down on good news, contrary to the worthless predictions of Lille John, Camelonen and whatever they are all called. They lost money on trading while the "øretrillere" have learned how to make money. One of them I know set a new personal best Friday with buying 2 øre over the lowest price and selling 4 øre under the highest price. 85 percent of the extremes at 44 øre. He also had luck this week as he was out of Circio when the news of the latest emission came. There are some losses too, but an average of 50 øre per week also turns into kroner. Almost every week. Yes, we all cheer for Circio, but put away the envy of important, lucrative traders.
·4 t sittenRollercoaster
Ha ha, that's great. Had completely forgotten that Uncle Scrooge bathed in his money. So nostalgic and it reminds me that I can mentally do the same soon.💰💰
·4 t sittenhttps://www.dn.no/bors/dn-investor/oslo-bors/sparing-og-investering/alfred-24-tjente-12-mill-pa-borsen-hadde-vart-fett-a-bli-drammens-rikeste/2-1-2040519?fbclid=IwVERDUAUceAhwZG9mBWV4dG4DYWVtAjEwAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHgLQGkw5H0O8SFbi_lDxhg9QflOFfaIglKSCdAS65f30ZEiBRrDEn5IvUKa5_aem_8UyVTEOtwn09UG6NGNjDDg Does anyone have access to the article?
If you have ambitions to become rich, then you should look at a mere subscription as an investment. It was an interesting article.
·12 t sittenSo, no idea about this forum and to sound less professional than the rest but what's happening... It's a huge rollercoaster.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
19 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenThought I'd share some thoughts on Circio's strategy going forward, especially the delivery side and how the capital from the latest round – and a potential repair issue – can be used. Circio owns the expression engine (circVec), but delivery still needs to be solved. Therefore, they are testing several things in parallel. Named collaborations on the delivery/vector side: • Acuitas – T-cell-tropic LNP (reported long-lasting expression) • Full Circles – C4DNA (minicircular format, potential for lower immune activation and re-dosing) • Tcelltech – nanoSMAR (large payload, non-integrating DNA vector) • United Immunity – CAR-M / myeloid-directed • TraffikGene – peptide-based non-viral delivery In addition, the company has several unnamed tracks. According to H1/webcast, there are about 11 active collaborations within in vivo cell therapy (divided into T-cell delivery, DNA vector formats, and other applications), plus a number of gene therapy collaborations (incl. top-5 pharma). The goal is to find the combination of circVec + delivery that provides the best expression and function before talking about clinic. What the first ~200 MNOK can be used for: • Intensive screening of LNPs and DNA vectors • Secure access to the most promising delivery technology – primarily via license / option – possibly smaller technology acquisitions (IP/asset), not full acquisition • Finance functional PoC studies (CAR expression + actual activity against target cells) • Advance preclinical development, primate validation and prepare CMC/IND A potential repair issue is not set in stone. It can be canceled if the share trades below the subscription price over time. If it is carried out, it provides: • Stronger negotiating position in licensing • Greater room for maneuver for smaller strategic acquisitions / technology acquisitions • More extensive preclinical programs and deeper primate validation • Better funded CMC and IND preparations • A buffer to build upon the technology that actually works best Large, established delivery companies are out of reach anyway. The realistic options are licenses with options, smaller asset acquisitions, or – with extra capital – a small early-stage acquisition. The order seems logical: 1. Screening 2. Find the right delivery 3. Connect it with circVec 4. Functional in vivo CAR-T PoC 5. Primate validation 6. CMC / preclinical development 7. Clinic If they manage to make this chain connect, they will have elevated the company from an expression technology to a more complete in vivo CAR-T platform. There is still much that needs to be proven – especially that the signal actually comes from the T-cells and that it functions functionally. But with the capital in place, they at least have the opportunity to test it properly. Anyone else have thoughts on this?
- ·1 t sittenBeyond the residents of the echo chamber's daily analyses of today's closing price, recommendations to hold or buy more on every dip, they also operate morally on a higher level. Losses don't matter either because one is, after all, supporting important medical research. The moral indignation is clearly expressed towards the traders. Long ago given the label "øretrillere". While FOMO is cultivated daily with stories about the train -the one train- that is about to leave the platform, the traders ensure liquidity in the stock. We have all been stuck in stocks without turnover. Time and again Circio goes down on good news, contrary to the worthless predictions of Lille John, Camelonen and whatever they are all called. They lost money on trading while the "øretrillere" have learned how to make money. One of them I know set a new personal best Friday with buying 2 øre over the lowest price and selling 4 øre under the highest price. 85 percent of the extremes at 44 øre. He also had luck this week as he was out of Circio when the news of the latest emission came. There are some losses too, but an average of 50 øre per week also turns into kroner. Almost every week. Yes, we all cheer for Circio, but put away the envy of important, lucrative traders.
- ·4 t sittenRollercoasterHa ha, that's great. Had completely forgotten that Uncle Scrooge bathed in his money. So nostalgic and it reminds me that I can mentally do the same soon.💰💰
- ·4 t sittenhttps://www.dn.no/bors/dn-investor/oslo-bors/sparing-og-investering/alfred-24-tjente-12-mill-pa-borsen-hadde-vart-fett-a-bli-drammens-rikeste/2-1-2040519?fbclid=IwVERDUAUceAhwZG9mBWV4dG4DYWVtAjEwAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHgLQGkw5H0O8SFbi_lDxhg9QflOFfaIglKSCdAS65f30ZEiBRrDEn5IvUKa5_aem_8UyVTEOtwn09UG6NGNjDDg Does anyone have access to the article?If you have ambitions to become rich, then you should look at a mere subscription as an investment. It was an interesting article.
- ·12 t sittenSo, no idea about this forum and to sound less professional than the rest but what's happening... It's a huge rollercoaster.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 472 | - | - | ||
| 1 528 | - | - | ||
| 2 500 | - | - | ||
| 3 385 | - | - | ||
| 3 778 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
19 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenThought I'd share some thoughts on Circio's strategy going forward, especially the delivery side and how the capital from the latest round – and a potential repair issue – can be used. Circio owns the expression engine (circVec), but delivery still needs to be solved. Therefore, they are testing several things in parallel. Named collaborations on the delivery/vector side: • Acuitas – T-cell-tropic LNP (reported long-lasting expression) • Full Circles – C4DNA (minicircular format, potential for lower immune activation and re-dosing) • Tcelltech – nanoSMAR (large payload, non-integrating DNA vector) • United Immunity – CAR-M / myeloid-directed • TraffikGene – peptide-based non-viral delivery In addition, the company has several unnamed tracks. According to H1/webcast, there are about 11 active collaborations within in vivo cell therapy (divided into T-cell delivery, DNA vector formats, and other applications), plus a number of gene therapy collaborations (incl. top-5 pharma). The goal is to find the combination of circVec + delivery that provides the best expression and function before talking about clinic. What the first ~200 MNOK can be used for: • Intensive screening of LNPs and DNA vectors • Secure access to the most promising delivery technology – primarily via license / option – possibly smaller technology acquisitions (IP/asset), not full acquisition • Finance functional PoC studies (CAR expression + actual activity against target cells) • Advance preclinical development, primate validation and prepare CMC/IND A potential repair issue is not set in stone. It can be canceled if the share trades below the subscription price over time. If it is carried out, it provides: • Stronger negotiating position in licensing • Greater room for maneuver for smaller strategic acquisitions / technology acquisitions • More extensive preclinical programs and deeper primate validation • Better funded CMC and IND preparations • A buffer to build upon the technology that actually works best Large, established delivery companies are out of reach anyway. The realistic options are licenses with options, smaller asset acquisitions, or – with extra capital – a small early-stage acquisition. The order seems logical: 1. Screening 2. Find the right delivery 3. Connect it with circVec 4. Functional in vivo CAR-T PoC 5. Primate validation 6. CMC / preclinical development 7. Clinic If they manage to make this chain connect, they will have elevated the company from an expression technology to a more complete in vivo CAR-T platform. There is still much that needs to be proven – especially that the signal actually comes from the T-cells and that it functions functionally. But with the capital in place, they at least have the opportunity to test it properly. Anyone else have thoughts on this?
- ·1 t sittenBeyond the residents of the echo chamber's daily analyses of today's closing price, recommendations to hold or buy more on every dip, they also operate morally on a higher level. Losses don't matter either because one is, after all, supporting important medical research. The moral indignation is clearly expressed towards the traders. Long ago given the label "øretrillere". While FOMO is cultivated daily with stories about the train -the one train- that is about to leave the platform, the traders ensure liquidity in the stock. We have all been stuck in stocks without turnover. Time and again Circio goes down on good news, contrary to the worthless predictions of Lille John, Camelonen and whatever they are all called. They lost money on trading while the "øretrillere" have learned how to make money. One of them I know set a new personal best Friday with buying 2 øre over the lowest price and selling 4 øre under the highest price. 85 percent of the extremes at 44 øre. He also had luck this week as he was out of Circio when the news of the latest emission came. There are some losses too, but an average of 50 øre per week also turns into kroner. Almost every week. Yes, we all cheer for Circio, but put away the envy of important, lucrative traders.
- ·4 t sittenRollercoasterHa ha, that's great. Had completely forgotten that Uncle Scrooge bathed in his money. So nostalgic and it reminds me that I can mentally do the same soon.💰💰
- ·4 t sittenhttps://www.dn.no/bors/dn-investor/oslo-bors/sparing-og-investering/alfred-24-tjente-12-mill-pa-borsen-hadde-vart-fett-a-bli-drammens-rikeste/2-1-2040519?fbclid=IwVERDUAUceAhwZG9mBWV4dG4DYWVtAjEwAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHgLQGkw5H0O8SFbi_lDxhg9QflOFfaIglKSCdAS65f30ZEiBRrDEn5IvUKa5_aem_8UyVTEOtwn09UG6NGNjDDg Does anyone have access to the article?If you have ambitions to become rich, then you should look at a mere subscription as an investment. It was an interesting article.
- ·12 t sittenSo, no idea about this forum and to sound less professional than the rest but what's happening... It's a huge rollercoaster.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 472 | - | - | ||
| 1 528 | - | - | ||
| 2 500 | - | - | ||
| 3 385 | - | - | ||
| 3 778 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt